Search

References

  1. Academy for Educational Development (AED), Hepatitis C virus and HIV coinfection. Washington, DC, 2002. Data retrieved 7/20/2010 from http://www.cdc.gov/idu/hepatitis/hepc_and_hiv_co.pdf (PDF, 45KB).
  2. Alessi, S.M.; Hanson, T.; Wieners, M.; and Petry, N.M. Low-cost contingency management in community clinics: Delivering incentives partially in group therapy. Experimental and Clinical Psychopharmacol 15(3):293-300, 2007.
  3. Des Jarlais, D.C.; Arasteh, K.; Perlis, T.; Hagan, H.; Abdul- Quader, A.; Heckathorn, D.D.; McKnight, C.; Bramson, H.; Nemeth, C.; Torian, L.V.; and Friedman, S.R. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 21(2):231-235, 2007.
  4. Gold, M.S. Cocaine (and crack): Clinical aspects. In: Lowinson, J.H., ed. Substance Abuse: A Comprehensive Textbook, 4th edition, Baltimore: Williams & Wilkins, pp. 218-251, 2005.
  5. Hagan, H.; Des Jarlais, D.C.; Stern, R.; Lelutiu- Weinberger, C.; Scheinmann, R.; Strauss, S.; and Flom, P.L. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 18:341-351, 2007.
  6. Johnston, L.D.; O'Malley, P.M.; Bachman, J.G.; and Schulenberg, J.E. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2009. DHHS Pub. No. 10-7583. Bethesda, MD: NIDA, 2010.
  7. Karila, L.; Gorelick, D.; Weinstein, A.; Noble, F.; Benyamina, A.; Coscas, S.; Blecha, L.; Lowenstein, W.; Martinot, J.L.; Reynaud, M.; and Lepine, J.P. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol, 11(3):425-438, 2007.
  8. Orson F.M.; Kinsey, B.M.; Singh, R.A.K.; Wu, Y.; and Kosten, T.R. Vaccines for cocaine abuse. Human vaccines, 5(4):194-199, 2009.
  9. Sokoloff, P.; Diaz, J.; Le Foll, B.; Guillin, O.; Leriche, L.; Bezard, E.; and Gross, C. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5(1):25-43, 2006.
  10. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, Detailed Tables: National Estimates of Drug-Related Emergency Department Visits 2004-2008. Data retrieved 7/20/2010 from http://www.samhsa.gov/data/DAWN.aspx.
  11. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: National Findings. DHHS Pub. No. SMA 09-4443, Rockville, MD: SAMHSA, 2009.
  12. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights-2007. National Admissions to Substance Abuse Treatment Services. DHHS Pub. No. SMA 09-4360, Rockville, MD: SAMHSA, 2009.
  13. Suh, J.J.; Pettinati, H.M.; Kampman, K.M.; and O'Brien, C.P. The status of disulfiram: A half of a century later. J Clin Psychopharmacol 26(3):290-302, 2006.
  14. Tseng, F.C.; O'Brien, T.R.; Zhang, M.; Kral, A.H.; Ortiz-Conde, B.A.; Lorvick, J.; Busch, M.P.; and Edlin, B.R. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 46(3):666-671, 2007.
  15. Volkow, N.D.; Wang, G.-J.; Fowler, J.S.; Logan, J.; Gatley, S.J.; Hitzemann, R.; Chen, A.D.; Dewey, S.L.; and Pappas, N. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386(6627):830-833, 1997.

This page was last updated September 2010

Page Tools